Trevena, Inc.
(NASDAQ : TRVN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.47%73.670.9%$618.75m
CELGCelgene Corporation
1.85%129.791.1%$445.74m
AMGNAmgen Inc.
1.25%170.261.1%$413.20m
BIIBBiogen Inc.
1.29%286.801.2%$361.25m
REGNRegeneron Pharmaceuticals, Inc.
2.27%480.402.7%$326.02m
VRTXVertex Pharmaceuticals Incorporated
3.34%153.991.9%$237.44m
ALXNAlexion Pharmaceuticals, Inc.
3.21%137.711.9%$221.48m
ILMNIllumina, Inc.
1.60%193.733.5%$218.17m
INCYIncyte Corporation
1.03%122.142.6%$133.13m
CLVSClovis Oncology, Inc.
-0.58%70.7918.0%$128.45m
KITEKite Pharma, Inc.
1.79%136.3016.1%$127.11m
TSROTESARO, Inc.
-0.30%118.5014.7%$123.72m
AAgilent Technologies, Inc.
1.44%62.631.5%$122.22m
BMRNBioMarin Pharmaceutical Inc.
0.92%81.344.4%$106.93m
SRPTSarepta Therapeutics, Inc.
0.81%36.0219.8%$98.22m

Company Profile

Trevena, Inc. is a clinical stage biopharmaceutical company. It discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors. The company product pipeline consists of TRV027, TRV130, TRV734, and Delta Opiod. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in King of Prussia, PA.